NCT03967223 2026-02-25IGNYTE-ESOUSWM, LLC (dba US WorldMeds)Phase 2 Active not recruiting103 enrolled
NCT03697824 2019-10-29Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1aGlaxoSmithKlinePhase 2 Withdrawn